{"filing":{"accession_number":"0001628280-26-044747","cik":"0001516551","ticker":"SKYE","company_name":"Skye Bioscience, Inc.","form":"8-K","filing_date":"2026-06-22","report_date":null,"primary_document":"skye-20260618.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1516551/000162828026044747/skye-20260618.htm"},"events":[{"id":12918,"run_id":11459,"accession_number":"0001628280-26-044747","anchor_item_number":"8.01","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.95,"summary":"The filing discloses two material listing compliance failures: (1) stockholders' equity of $9.0 million fell below the $10 million Nasdaq Global Market minimum, triggering a transfer to Nasdaq Capital Market effective June 23, 2026; and (2) the stock price has closed below the $1.00 minimum bid price requirement for 30 consecutive business days, with an initial 180-day cure period ending September 14, 2026. The company explicitly acknowledges \"there can be no assurance that the Company will be able to regain compliance,\" creating a material delisting risk that would substantially affect investor assessment of the registrant's continued listing status.","company_name":"Skye Bioscience, Inc.","ticker":"SKYE","filing_date":"2026-06-22","form":"8-K","submitted_at":null,"items":[{"id":9907,"accession_number":"0001628280-26-044747","item_number":"8.01","item_title":"Other Events.","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.95,"reasoning":"The filing discloses two material listing compliance failures: (1) stockholders' equity of $9.0 million fell below the $10 million Nasdaq Global Market minimum, triggering a transfer to Nasdaq Capital Market effective June 23, 2026; and (2) the stock price has closed below the $1.00 minimum bid price requirement for 30 consecutive business days, with an initial 180-day cure period ending September 14, 2026. The company explicitly acknowledges \"there can be no assurance that the Company will be able to regain compliance,\" creating a material delisting risk that would substantially affect investor assessment of the registrant's continued listing status.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-23T10:01:59.403662+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":9907,"accession_number":"0001628280-26-044747","item_number":"8.01","item_title":"Other Events.","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.95,"reasoning":"The filing discloses two material listing compliance failures: (1) stockholders' equity of $9.0 million fell below the $10 million Nasdaq Global Market minimum, triggering a transfer to Nasdaq Capital Market effective June 23, 2026; and (2) the stock price has closed below the $1.00 minimum bid price requirement for 30 consecutive business days, with an initial 180-day cure period ending September 14, 2026. The company explicitly acknowledges \"there can be no assurance that the Company will be able to regain compliance,\" creating a material delisting risk that would substantially affect investor assessment of the registrant's continued listing status.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-23T10:01:59.403662+00:00","company_name":"Skye Bioscience, Inc.","ticker":"SKYE","filing_date":"2026-06-22"}]}